GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mainz Biomed N.V.
Mainz Biomed is a company developing tests for early cancer detection. Its stock price is a bet on the success of its flagship colorectal cancer screening product. The chart reflects investor expectations for clinical trials and a future commercial launch.
Share prices of companies in the market segment - Cancer analysis
Mainz Biomed is a molecular genetics company developing non-invasive diagnostic tests for the early detection of cancer, particularly colorectal cancer. We've categorized it as a "Cancer Analysis" company, and the chart below shows how the market views the prospects of companies in the oncology diagnostics sector.
Broad Market Index - GURU.Markets
Mainz Biomed develops and markets easy-to-use tests for the early detection of cancer, particularly colorectal cancer. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Mainz Biomed compares to it.
Change in the price of a company, segment, and market as a whole per day
MYNZ - Daily change in the company's share price Mainz Biomed N.V.
For Mainz Biomed N.V., a cancer diagnostics company, daily volatility reflects sensitivity to news about the introduction of its tests. This metric is an indicator of demand for non-invasive early diagnostic methods.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. The medical diagnostics sector is highly sensitive to news about clinical efficacy. The chart below shows the volatility in this niche, providing context for assessing MYNZ stock performance.
Daily change in the price of a broad market stock, index - GURU.Markets
Mainz Biomed is a German company specializing in colon cancer diagnostics. Its shares bring the dynamism of the European medtech sector to the US market. These international factors make the overall picture of market volatility more complex and global.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mainz Biomed N.V.
Mainz Biomed N.V.'s year-over-year performance is a story about the commercialization of its colorectal cancer early detection test. Its market capitalization growth over the past 12 months reflects its success in promoting the ColoAlert® test in Europe and progress toward FDA approval in the US, its primary goal and key catalyst.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Mainz Biomed is a molecular diagnostics company developing tests for the early detection of cancer. Its success depends on the widespread adoption of its innovative tests. This chart shows how the market perceives the commercial potential of its technology and its path to profitability.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mainz Biomed, a developer of early cancer diagnostic tests, particularly for colorectal cancer, strives to make screening more accessible and accurate. Its annual market capitalization growth reflects the enormous potential of the early diagnostics market and investor expectations for the commercialization of its products. Success could save millions of lives and generate enormous profits.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mainz Biomed N.V.
Mainz Biomed is a molecular diagnostics company developing tests for early cancer detection. Its monthly performance reflects progress in the commercialization of its ColoAlert test. News of regulatory approvals in the US is the main catalyst.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. The company's success depends on the accuracy of its tests and their acceptance by the medical community. The medical diagnostics sector's performance reflects the general interest in early screening, which is a tailwind for innovative products like those offered by Mainz Biomed.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mainz Biomed develops tests for the early detection of cancer, particularly colorectal cancer. This is a promising area of medicine. The company's stock performance is loosely linked to the market and is driven by the success of its tests in commercializing, obtaining regulatory approvals, and clinical trial results confirming their accuracy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mainz Biomed N.V.
Mainz Biomed develops tests for the early detection of cancer, particularly colorectal cancer. Its weekly stock price reflects news of the clinical validation of its tests, regulatory approvals, and its ability to compete with existing screening methods.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
Mainz Biomed develops tests for the early detection of cancer, particularly colorectal cancer. The company's shares are highly sensitive to news about the clinical validation and commercialization of its products. The chart clearly shows how its performance differs from the average for the medical diagnostics sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Mainz Biomed develops tests for early cancer detection. Its shares are a bet on the success of its medical technologies. The chart clearly shows how its performance is detached from the broader market and driven by news of clinical validation and commercialization.
Market capitalization of the company, segment and market as a whole
MYNZ - Market capitalization of the company Mainz Biomed N.V.
Mainz Biomed's market capitalization chart reflects investors' valuation of its noninvasive colorectal cancer diagnostic test. Its performance reflects the market's belief that its easy-to-use test can become a standard for screening. Its value is a bet on successful clinical trials and future sales in the vast early cancer diagnostic market.
MYNZ - Share of the company's market capitalization Mainz Biomed N.V. within the market segment - Cancer analysis
Mainz Biomed develops non-invasive tests for the early detection of cancer. Its market share in the medical technology sector is small, but it is focused on mass screening. Its market cap is based on the potential of its flagship ColoAlert colorectal cancer test, which could become an alternative to colonoscopy.
Market capitalization of the market segment - Cancer analysis
Below is a graph showing the total value of the entire oncology diagnostics sector. For Mainz Biomed, which is developing a non-invasive test for the early detection of colorectal cancer, this line represents a map of the future. The rising graph reflects the global trend toward early diagnosis, which is key to successful cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Its market capitalization is determined by the value of non-invasive diagnostics. This is the market share of businesses that enable early and curable cancer detection.
Book value capitalization of the company, segment and market as a whole
MYNZ - Book value capitalization of the company Mainz Biomed N.V.
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Its book value is its scientific and financial capital. It consists of funds allocated for research and commercialization of tests. How has this capital changed? The chart below shows.
MYNZ - Share of the company's book capitalization Mainz Biomed N.V. within the market segment - Cancer analysis
Mainz Biomed N.V. develops tests for early cancer detection. Its business relies on its own and partner laboratories, where research is conducted and ColoAlert tests are processed. The chart shows the company's share of the physical infrastructure required for next-generation medical diagnostics.
Market segment balance sheet capitalization - Cancer analysis
Mainz Biomed is a diagnostics company. Compared to the capital-intensive healthcare sector, its model is knowledge-intensive. The industry's asset chart reflects the value of hospitals. Mainz, on the other hand, invests in laboratories and R&D to develop its tests.
Book value of all companies included in the broad market index - GURU.Markets
Mainz Biomed's assets include laboratories and commercial infrastructure for its non-invasive tests for the early detection of colorectal cancer. Its book value reflects its potential in this important area of oncology, offering an alternative to colonoscopy. The chart illustrates the scale of this German diagnostics company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mainz Biomed N.V.
Mainz Biomed develops tests for the early detection of cancer, particularly colorectal cancer. Its market value is based on its technology and its potential to make diagnosis simpler and more accessible. It's betting that its test will become a new standard.
Market to book capitalization ratio in a market segment - Cancer analysis
Mainz Biomed develops tests for the early detection of cancer, particularly colorectal cancer. Its value lies in its technology. The chart shows a high premium to its tangible assets, as investors are betting that its tests will become the new standard in screening.
Market to book capitalization ratio for the market as a whole
Mainz Biomed develops tests for early cancer detection. Its key asset is its technology and intellectual property, not its laboratories. This chart shows the high premium investors are willing to pay for medical innovations that can save lives and capture huge markets, even in the early stages of development.
Debts of the company, segment and market as a whole
MYNZ - Company debts Mainz Biomed N.V.
Mainz Biomed, a company developing diagnostic tests for early cancer detection, is raising capital to finance clinical trials and the commercial launch of its products. This chart shows the significant investment required to bring a new medical test to market, which must prove its accuracy and reliability.
Market segment debts - Cancer analysis
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Its flagship product is an easy-to-use at-home test. This chart shows how the company is funding clinical trials to obtain FDA approval and commercialize its product in the vast but competitive cancer diagnostics market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mainz Biomed N.V.
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. Commercializing medical tests requires significant investment in clinical trials to confirm accuracy and marketing. This chart shows how the company is using debt to finance its path to market and compete in the oncology diagnostics field.
Market segment debt to market segment book capitalization - Cancer analysis
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. This is a promising but capital-intensive field. This chart shows how the company finances its research and commercialization. It compares its debt to the market capitalization of the entire medical diagnostics sector.
Debt to book value of all companies in the market
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Medical diagnostics require significant investment in clinical research and commercialization. How dependent is the company on debt? This chart of total market debt provides context for assessing its financial strategy on the path to profitability.
P/E of the company, segment and market as a whole
P/E - Mainz Biomed N.V.
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. This chart shows how investors value its non-invasive tests. This value is dependent on clinical trial results, regulatory approvals, and acceptance by the medical community.
P/E of the market segment - Cancer analysis
Mainz Biomed is a molecular genetic diagnostics company specializing in the development of tests for the early detection of cancer, particularly colorectal cancer. This chart illustrates the average valuation in the oncology diagnostics sector, where investors highly value the potential of non-invasive tests to save lives through early disease detection.
P/E of the market as a whole
Mainz Biomed N.V. develops and commercializes easy-to-use diagnostic tests for the early detection of cancer, with a particular focus on colorectal cancer. This chart reflects general trends in the healthcare sector. It helps us understand whether MYNZ is valued as an innovative diagnostics company with significant potential or whether its value is moving in tandem with overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mainz Biomed N.V.
Mainz Biomed develops non-invasive diagnostic tests for the early detection of cancer, particularly colorectal cancer. Their flagship product offers a simple alternative to colonoscopy. This chart illustrates the investors' confidence in the commercial potential of this test and its ability to become a new standard in cancer screening, opening up a huge market.
%20P%2FE%20Mainz%20Biomed%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mainz-Biomed-N.V.&v=1772644883076 "Chart of the company's future (projected) P/E Mainz Biomed N.V.")
Future (projected) P/E of the market segment - Cancer analysis
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Its goal is to make diagnostics simple and accessible. The chart reflects future revenue forecasts for the sector. It helps understand how highly the market values the potential of Mainz Biomed's tests to save lives and achieve commercial success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772644883148 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. Early detection is a key trend in healthcare. This market sentiment chart shows how willing investors are to invest in companies whose technologies could revolutionize screening and save millions of lives.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772644883218 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mainz Biomed N.V.
Mainz Biomed N.V. develops and commercializes easy-to-use diagnostic tests for the early detection of cancer, particularly colorectal cancer. Profitability depends on the widespread adoption of its tests. This chart shows the financial results of the company, whose mission is to make cancer diagnostics more accessible and save lives.
Profit of companies in the market segment - Cancer analysis
Mainz Biomed N.V. develops and commercializes non-invasive diagnostic tests for the early detection of cancer, particularly colorectal cancer. Early diagnosis saves lives. This chart shows the overall profitability of the cancer testing sector, where convenient and accurate population screening tests have enormous commercial potential.
Overall market profit
Mainz Biomed N.V. develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Demand for these diagnostics is driven by healthcare system needs and screening programs. This market is independent of the economic cycles visible in the chart, as early cancer detection is a priority in any economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mainz Biomed N.V.
Mainz Biomed develops non-invasive diagnostic tests for the early detection of cancer, particularly colorectal cancer. Future profits depend on the commercial success of its tests and regulatory approvals in key markets. This chart shows whether analysts believe its cancer screening products will be widely adopted.
%20profit%20of%20the%20company%20Mainz%20Biomed%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mainz-Biomed-N.V.&v=1772644883341 "Graph of future (projected) profit of the company Mainz Biomed N.V.")
Future (predicted) profit of companies in the market segment - Cancer analysis
Mainz Biomed develops non-invasive tests for the early detection of cancer, primarily colorectal cancer. Its goal is to make screening simpler and more accessible, potentially saving lives. The company's success depends on the adoption of its tests. This chart shows revenue projections for the cancer diagnostics sector, helping to assess Mainz Biomed's potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772644883376 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Mainz Biomed N.V. develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Demand for these tests depends on healthcare spending and the implementation of screening programs. This economic outlook influences healthcare system budgets and their focus on preventive care.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772644883393 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mainz Biomed N.V.
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Revenue growth reflects the acceptance of its tests by the medical system. This chart shows how investors view its technology and its potential to transform approaches to cancer screening.
P/S market segment - Cancer analysis
Mainz Biomed develops and commercializes innovative diagnostic tests for the early detection of cancer. Their flagship product is an easy-to-use colorectal cancer screening test that has the potential to save countless lives. This chart shows the average revenue estimate for the sector, helping to understand how the market views the potential of Mainz Biomed's tests.
P/S of the market as a whole
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer, using DNA analysis. This chart highlights that the valuation of companies in the medical diagnostics sector depends on the accuracy of their tests, the size of their target market, and their ability to obtain regulatory approval, not just their current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mainz Biomed N.V.
Mainz Biomed develops non-invasive diagnostic tests for the early detection of cancer, particularly colorectal cancer. Estimating future revenue is critical for a diagnostic company like this. It reflects investor expectations for the commercial success of its tests and their widespread adoption in screening practices, which could save countless lives and create a huge market.
%20P%2FS%20Mainz%20Biomed%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mainz-Biomed-N.V.&v=1772644883604 "The graph of the company's future (projected) P/S Mainz Biomed N.V.")
Future (projected) P/S of the market segment - Cancer analysis
Mainz Biomed develops and commercializes diagnostic tests for the early detection of cancer, specifically a noninvasive test for colorectal cancer. This chart compares the company's estimated future sales with expectations for the medical diagnostics sector. It shows whether investors believe its test will become a widely adopted tool for cancer screening and prevention.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772644883742 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. The company's growth depends on the successful commercialization and widespread adoption of its diagnostic products. This graph of investor expectations reflects their belief that early detection is key to successful treatment and has enormous market potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772644883764 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mainz Biomed N.V.
For Mainz Biomed, this figure reflects revenue from sales of its core product—a noninvasive test for the early detection of colorectal cancer. Revenue growth is directly dependent on the successful commercialization of this test in Europe and the US, as well as its acceptance by the medical community as an effective screening tool.
Sales of companies in the market segment - Cancer analysis
Mainz Biomed develops and commercializes diagnostic tests for the early detection of cancer. Its revenue is generated by sales of the ColoAlert colorectal cancer screening test in Europe. The country-by-country sales breakdown demonstrates the success of its international expansion, and future revenue depends on its entry into the US market.
Overall market sales
Mainz Biomed N.V. develops easy-to-use diagnostic tests for the early detection of cancer, particularly colorectal cancer. The company strives to make diagnostics more accessible. This general economic outlook does not affect the fundamental need for early diagnosis, which saves lives, making Mainz Biomed's mission relevant in any economic climate.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mainz Biomed N.V.
Mainz Biomed develops and commercializes diagnostic tests for the early detection of cancer, primarily colorectal cancer. Its main product is a noninvasive screening test. Sales growth depends on its adoption in clinical practice. This chart shows analysts' forecasts for demand for convenient and accurate early cancer detection methods.
%20sales%20of%20the%20company%20Mainz%20Biomed%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mainz-Biomed-N.V.&v=1772644883846 "Schedule of future (projected) sales of the company Mainz Biomed N.V.")
Future (projected) sales of companies in the market segment - Cancer analysis
Mainz Biomed N.V. develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. This chart illustrates the forecast for the medical testing market. Is demand growing for convenient and accurate screening tests that can save lives? This determines the overall outlook for the diagnostics industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772644883873 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Demand for such tests is driven by screening programs and public awareness, not economic cycles. This timeframe is of minimal importance, as early cancer detection is a healthcare priority in any economic situation.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772644883902 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mainz Biomed N.V.
Mainz Biomed develops noninvasive diagnostic tests for the early detection of cancer, particularly colorectal cancer. This chart shows the company's financial trajectory during the commercialization phase. Profitability depends on widespread acceptance of its tests by physicians and patients, as well as insurance coverage, which is a key factor for success in medical diagnostics.
Market segment marginality - Cancer analysis
Mainz Biomed N.V. develops and commercializes diagnostic tests for the early detection of cancer, particularly colorectal cancer. The company's profitability depends on the successful launch of its tests, their acceptance by physicians and patients, and reimbursement from insurance companies. This chart shows its path to profitability in the important field of medical diagnostics.
Market marginality as a whole
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Demand for its products depends on the implementation of screening programs. This overall profitability chart reflects the state of the healthcare system and its focus on preventive medicine, which intensifies during periods of economic stability.
Employees in the company, segment and market as a whole
Number of employees in the company Mainz Biomed N.V.
Mainz Biomed develops non-invasive tests for the early detection of cancer, particularly colorectal cancer. Its team of scientists and market access specialists is key to its success. This chart shows how the company is expanding its staff to conduct clinical trials and prepare for the commercial launch of its diagnostic test in Europe and the US.
Share of the company's employees Mainz Biomed N.V. within the market segment - Cancer analysis
Mainz Biomed develops and commercializes diagnostic tests for the early detection of cancer, particularly colorectal cancer. Sales and processing of these tests require a team of sales specialists, lab technicians, and scientists. This graph shows the company's market share in the medical diagnostics sector, and its growth may reflect the success of its product launch.
Number of employees in the market segment - Cancer analysis
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. The company offers an easy-to-use test for home use. The chart shows employment in the cancer testing sector. Early detection significantly increases the chances of successful treatment, making Mainz Biomed products potentially lifesaving.
Number of employees in the market as a whole
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. Its growth depends on the commercialization and implementation of these tests in medical practice. This chart shows overall employment, and Mainz Biomed exemplifies how diagnostic innovations can create a new standard in medicine and, consequently, new jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mainz Biomed N.V. (MYNZ)
Mainz Biomed develops diagnostic tests for early cancer detection, such as their flagship ColoAlert test. This is an IP-dominated medtech sector. This chart shows the market's perceived value of their technology. It reflects the value of their R&D and patents per employee.
%20of%20the%20company%20Mainz%20Biomed%20N.V.%20(MYNZ)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mainz-Biomed-N.V.-MYNZ&v=1772644884101 "Chart of market capitalization per employee (in thousands of dollars) of the company Mainz Biomed N.V. (MYNZ)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Mainz Biomed (MYNZ) develops and commercializes easy-to-use diagnostic tests for cancer detection, particularly colorectal cancer. This chart for the diagnostic company shows the market valuation of its product. The high market capitalization per employee suggests that their ColoAlert test has the potential to become a global screening standard.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772644884131 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Mainz Biomed develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. In the medical diagnostics sector, the value lies in the accuracy and convenience of the test. The graph shows a high employee rating, as the market sees enormous potential in a non-invasive test that could save millions of lives and capture a large market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772644884143 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mainz Biomed N.V. (MYNZ)
Mainz Biomed is a company developing non-invasive diagnostic tests for the early detection of cancer (primarily colorectal). This chart shows the company's current stage. It reflects how much profit (or loss) the R&D and marketing team is generating as they launch their tests in the European and American markets.
%20Chart%20Mainz%20Biomed%20N.V.%20(MYNZ)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mainz-Biomed-N.V.-MYNZ&v=1772644884167 "Company Profit Per Employee (in thousands of dollars) Chart Mainz Biomed N.V. (MYNZ)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Mainz Biomed N.V. develops diagnostic tests for the early detection of cancer, particularly colorectal cancer. In medical diagnostics, efficiency per employee reflects the scientific value and commercial potential of their tests. This chart allows one to evaluate how R&D investments translate into financial returns and compare this with other companies in the sector.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772644884258 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Mainz Biomed is a company focused on early cancer detection. Their flagship product is ColoAlert, a non-invasive colorectal cancer screening test. They are in the medtech/diagnostics space. This chart shows how a sector where value is created by R&D and laboratory technology compares in terms of personnel efficiency compared to a market dominated by other models.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772644884292 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mainz Biomed N.V. (MYNZ)
Mainz Biomed develops diagnostic tests for the early detection of cancer. This schedule is crucial during the commercialization phase. Increasing revenue per employee will indicate the successful implementation of their tests in clinical practice, enabling the small team to generate significant revenue from sales of this high-tech product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mainz-Biomed-N.V.-MYNZ&v=1772644884376 "Sales chart per company employee Mainz Biomed N.V. (MYNZ)")
Sales per employee in the market segment - Cancer analysis
Mainz Biomed is a company focused on molecular cancer diagnostics. Their flagship product is ColoAlert, a noninvasive stool test for the early detection of colorectal cancer. This graph shows the average production in the sector. For MYNZ, this is an indicator of how productive their R&D and sales teams are in commercializing this important test.
Sales per employee for the market as a whole
Mainz Biomed is a company specializing in molecular diagnostics. Their flagship product is ColoAlert, an easy-to-use test for the early detection of colon cancer. This indicator demonstrates the effectiveness and scalability of their business model (selling diagnostic kits).
Short shares by company, segment and market as a whole
Shares shorted by company Mainz Biomed N.V. (MYNZ)
Mainz Biomed (MYNZ) develops noninvasive tests for the early detection of cancer, particularly colon cancer. This chart shows the number of short positions. Sellers may doubt the test's accuracy compared to the existing gold standard (colonoscopy) or the company's ability to gain FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mainz-Biomed-N.V.-MYNZ&v=1772644884504 "Short Shares Chart for the Company Mainz Biomed N.V. (MYNZ)")
Shares shorted by market segment - Cancer analysis
Mainz Biomed (MYNZ) develops non-invasive tests for early cancer detection, specifically the ColoAlert colorectal cancer screening test. This chart shows the total short position in the medical diagnostics sector. It reflects investor skepticism regarding competition from existing methods (colonoscopy) and the risks of approval.
Shares shorted by the overall market
Mainz Biomed (MYNZ) is an R&D company developing cancer diagnostics. It's a speculative bet. When this market fear indicator rises, investors' risk appetite plummets. They sell off unprofitable stocks like MYNZ, whose fate depends on R&D and regulatory approval.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mainz Biomed N.V. (MYNZ)
Mainz Biomed (MYNZ) develops easy-to-use diagnostic tests for the early detection of cancer, particularly colorectal cancer (ColoAlert). It's a huge market. This chart measures the rate of price change. It shows when the stock is "overheated" (above 70) due to positive test accuracy data or "oversold" (below 30) due to profit-taking.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mainz-Biomed-N.V.-MYNZ&v=1772644884644 "RSI 14 indicator chart for the company's stock Mainz Biomed N.V. (MYNZ)")
RSI 14 Market Segment - Cancer analysis
Mainz Biomed is a company specializing in molecular cancer diagnostics. Its key product is an easy-to-use DNA test (ColoAlert) for the early detection of colorectal cancer. This chart shows the overall sentiment in the medical diagnostics and testing sector. It helps understand how investors view the industry and how Mainz Biomed compares to its competitors.
RSI 14 for the overall market
Mainz Biomed (MYNZ), a cancer diagnostics company, is critically dependent on sentiment, as reflected in this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs, and MYNZ risks being left without funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MYNZ (Mainz Biomed N.V.)
Mainz Biomed is a German company that developed ColoAlert, a highly accurate and convenient DNA test for home-based colon cancer detection. This chart shows the average price target from analysts, based on their expectations for FDA approval and commercial success of this test in the US market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MYNZ-Mainz-Biomed-N.V.&v=1772644884776 "A chart showing analyst consensus forecasts for the expected stock price. MYNZ (Mainz Biomed N.V.)")
The difference between the consensus estimate and the actual stock price MYNZ (Mainz Biomed N.V.)
Mainz Biomed is a diagnostic company developing ColoAlert, a non-invasive (at-home) test for the early detection of colon cancer using DNA. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the commercial success of this screening test.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MYNZ-Mainz-Biomed-N.V.&v=1772644884789 "A chart showing the difference between the consensus forecast and the actual stock price. MYNZ (Mainz Biomed N.V.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Mainz Biomed (MYNZ) is a diagnostic company developing tests (ColoAlert) for the early detection of colorectal cancer based on DNA analysis. This chart shows analysts' overall expectations for the cancer testing sector. It reflects whether experts believe the market for "non-invasive" tests as an alternative to colonoscopy will grow.
Analysts' consensus forecast for the overall market share price
Mainz Biomed is a company specializing in early cancer detection. Their flagship product is ColoAlert, a noninvasive stool test for colon cancer screening. This chart shows overall market sentiment. For Mainz, which operates in the "defensive" healthcare sector, overall optimism is important, but their growth depends more on the test's acceptance by insurance companies and physicians.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mainz Biomed N.V.
Mainz Biomed is a diagnostic detective. Their signature product is ColoAlert, a non-invasive (at-home) stool DNA test for the early detection of colon cancer. It is a European competitor to Cologuard. This chart summarizes their implementation history. It reflects their progress toward FDA approval (their primary goal) and their (still) speculative commercial potential.
AKIMA Market Segment Index - Cancer analysis
Mainz Biomed (MYNZ) is a German diagnostic company that has challenged colonoscopy. Their flagship product is ColoAlert, a non-invasive DNA-based home test that helps detect colon cancer at an early stage. This chart shows the segment's average index, helping investors assess how successful this diagnostic model is compared to the average.
The AKIM Index for the overall market
Mainz Biomed is a German diagnostic company specializing in early cancer detection (the ColoAlert colon cancer test). This chart, reflecting the market average, provides context. It helps assess how this commercialization story in Europe and the US compares to overall macroeconomic trends.
